Psychiatry, World Trade Center Research Program
Icahn School of Medicine at Mount Sinai
Dr. Aaronson’s clinical interests include panic disorder, generalized anxiety disorder, social anxiety, posttraumatic stress disorder, and depression. Her research involves developing new types of treatment interventions for PTSD, depression, and interventions to encourage initiation of and adherence to hepatitis C medication treatment.
Dr. Aaronson joined ADAA in 2004, was elected to the Board of Directors in 2013, and has been actively involved ever since.
Why I am a member of ADAA
I loved the ADAA conference the first time I attended in 2004, and I have been going every year since. Being a member means I am part of this amazing organization that is so welcoming but also extremely professional.
What I value about the ADAA mission and how it's a fit with my work
The focus is completely aligned with my interests and expertise—anxiety disorders and depression. I can network with other clinicians and researchers who do what I do and learn from them new ways to better treat my patients. We all want the same thing: to help those who suffer from anxiety and depression, but also to prevent the development of anxiety and depression in future generations.
What is most exciting and interesting in my lab
I am so fortunate to work with excellent researchers who are dedicated to uncovering what genetically and epigenetically contributes to the development of PTSD in those who are exposed to trauma, specifically 9/11. We are working on adapting an Internet-based treatment for PTSD that we can test for effectiveness. The goal is to make getting treatment less stigmatizing and more available to those in need.